This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acorda Receives Five Awards, Including PM360 Trailblazer Award As Best Specialty Pharma/Biotechnology Company

Acorda Therapeutics, Inc. (Nasdaq:  ACOR) today announced that the Company has recently received five awards recognizing its corporate accomplishments and digital marketing efforts, including the prestigious PM360 Trailblazer Award for Company of the Year in the category of Best Specialty Pharma/Biotechnology Company.

The Trailblazer Awards highlight outstanding achievement and innovation in healthcare marketing. In particular, Acorda was recognized for its pursuit of excellence in three separate areas: marketing and advertising, talent development and social responsibility. The award is presented by the widely-read PM360 magazine, a resource for marketing decision-makers in the pharmaceutical, biotech, and medical device industries. Award decisions are made by the PM360 Editorial Advisory Board, composed of distinguished healthcare marketing and other industry experts.

“We have more than 400 associates at Acorda who share the purpose of improving the lives of people with neurological diseases,” said Ron Cohen, M.D., Acorda's President and CEO. “This is a challenging goal that can only be achieved through commitment, perseverance and collaboration. It’s a privilege for all of us at Acorda to be recognized by PM360 for the contributions we are making to advance the care of people with these devastating illnesses.”

Acorda also was honored with three industry awards by three other prestigious organizations.

The American Business Association recognized the Company’s corporate web site, , with its 2013 Gold Stevie Award in the category of pharmaceutical website.

The Web Marketing Association selected both the consumer and healthcare professional sections of Acorda’s product website, , as winners of the 2013 Pharmaceuticals Standard of Excellence Award. The Web Marketing Association’s WebAward program is the longest running annual website award competition.

Medical Marketing & Media recognized with a Silver MM&M Award in the category of best branded website for consumers. This year's judging process included two comprehensive rounds of scoring by more than 100 independent judges who are seasoned industry professionals.

Dr. Cohen said, “Bringing innovative medications to market is just one element of our mission to improve patient lives. We also seek to provide a broad range of important health information to patients, healthcare professionals and patient advocacy communities, and our online initiatives are key elements of these programs. Being acknowledged by our peers for the caliber of these initiatives is both satisfying and hugely motivating.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs